Francisco Rivera
Nurse Practitioner · Tyler, TXNPI 1487742037
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,096 of the $11,301 with a category attached, or 71.6%. 26 manufacturers reported payments, led by Edwards Lifesciences at 35.0% of the total. 2025 is the largest year on record at $3,525, 2.1 times the $1,660 reported in 2021. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Novartis$2K
- Medtronic$1K
- Johnson & Johnson$747
- Merck$659
- AstraZeneca$577
- plus $3K from 20 others
What the payments were for
- Travel & lodging$3,06027%
- Food & beverage$8,09672%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 33 | $3,952 |
| Novartis | 100 | $1,564 |
| Medtronic | 15 | $1,091 |
| Johnson & Johnson(2 entities) | 29 | $747 |
| Merck | 35 | $659 |
| AstraZeneca | 16 | $577 |
| Pfizer | 26 | $444 |
| Amgen | 12 | $375 |
| Abiomed | 11 | $244 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $222 |
| Boehringer Ingelheim | 7 | $216 |
| Sanofi-aventis U.S. LLC | 3 | $166 |
| Boston Scientific | 8 | $164 |
| E.r. Squibb & Sons, L.L.C. | 9 | $149 |
| Novo Nordisk | 8 | $128 |
| Viiv Healthcare Company | 1 | $118 |
| Atricure, Inc. | 1 | $105 |
| Cvrx, Inc. | 4 | $65 |
| Altathera Pharmaceuticals LLC | 2 | $64 |
| Abbott | 3 | $63 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Bayer | 2 | $33 |
| Inari Medical, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $17 |
| Surmodics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPIEN 3 Ultra RESILIA$1,160
- Edwards SAPIEN 3 Transcatheter Heart Valve$964
- COREVALVE EVOLUT R$649
- XARELTO$272
- Repatha$236
- MULTAQ$122
- ANDEXXA$122
- APRETUDE$118
- AFFERA MAPPING SYSTEM$117
- JARDIANCE$108
- SYNERGY ABLATION SYSTEM$105
How this compares
$11,301 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 245 | $210,754 |
| JardianceEmpagliflozin | 228 | $178,137 |
| EntrestoSacubitril/Valsartan | 48 | $46,539 |
| XareltoRivaroxaban | 45 | $41,276 |
| MultaqDronedarone Hcl | 17 | $21,605 |
| FarxigaDapagliflozin Propanediol | 25 | $16,407 |
| Dofetilide | 18 | $1,445 |
| Carvedilol | 110 | $1,357 |
| Losartan Potassium | 96 | $1,120 |
| Metoprolol Succinate | 97 | $1,108 |
| Ranolazine ErRanolazine | 21 | $1,106 |
| Potassium Chloride | 74 | $874 |
| Amlodipine Besylate | 88 | $768 |
| Bumetanide | 19 | $675 |
| Atorvastatin Calcium | 69 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $444 | $210,754245 claims |
| Boehringer IngelheimJardiance | $216 | $178,137228 claims |
| NovartisEntresto | $1,564 | $46,53948 claims |
| Johnson & JohnsonXarelto | $747 | $41,27645 claims |
| Sanofi-aventis U.S. LLCMultaq | $166 | $21,60517 claims |
| AstraZenecaFarxiga | $577 | $16,40725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Tyler
- Roger ChapmanTyler$211K
- David McCaskillTyler$27K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Onna FeuchterSouthlake$108K
- Stephanie AgrellaRound Rock$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.